Get insight into the next EU Framework Programme
NanoImpactNet – QNano conference
The European Technology Platform
The ETP Nanomedicine, an initiative led by industry and set up together with the European Commission is addressing the application of nanotechnology to achieve breakthroughs in healthcare.
Nanomedicine exploits the improved and often novel physical, chemical and biological properties of materials at the nanometer scale. Nanomedicine has the potential to enable early detection and prevention, and to essentially improve diagnosis, treatment and follow-up of diseases.
The ETP supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
Become a member of the ETP Nanomedicine
Join Now!
| >>> Apply for
Membership |
- Featured News
-
Get insight into the next EU Framework Programme
The European Commission elaborated a proposal for the next Framework Programme for Research and Innovation named Horizon 2020. Get key data, the main objectives and overview of the structure in the following presentation.
New market research report on Nanotechnology in Medical Applications
The global nanomedicine market reached $63.8 billion in 2010 and $72.8 billion in 2011. The market is expected to grow to $130.9 billion by 2016 at a compound annual growth rate (CAGR) of 12.5% between years 2011 and 2016.
Call for Papers and Posters for the European Summit for Clinical Nanomedicine 2012
The call for Papers for the upcoming European Summit for Clinical Nanomedicine is open till 11th February 2012!
NANOFAR: New European Doctorate in Nanomedicine and Pharmaceutical Innovation
NANOFAR is a three-year PhD thesis in nanomedicine and pharmaceutical innovation, co-supervised by partners in two different countries and including a one-year mobility period.
Catalan Strategic Agenda of Nanobiotechnology published
The IBEC-coordinated Connect-EU Nanobio + Nanomed Working Group has published a 'roadmap' for nanobiotechnology capabilities in Catalonia.
Breaking down barriers to research – consultation on the European Research Area
The European Commission, DG Research and Innovation, launched on 13th September a public consultation on Breaking down barriers to research.
Nanobiotix Starts Clinical Trial with Lead Product NBTXR3
Paris, France - September 13th 2011 - Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
ETPN White Paper on "Improving Translation of Public Healthcare Nano-Research in Europe"
In this paper the ETP Nanomedicine together with the Nanomedicine community at large elaborates on the difficulties of translating research results in Nanomedicine from bench to bedside and from lab to products and provides four recommendations for actions to improve Nanomedicine research & development in Europe.
New article published: How do we develop nanopharmaceuticals under open innovation?
Following article from Mike Eaton has been published in the nanomedicine journal.
EUMINAfab 5th Call for Proposals
EUMINAfab: European Research Infrastructure for multimaterial micro and nano fabrication and characterization opens the 5th call for no fee access to 37 installations containing equipment to high end micro and nano technologies.
Launch of the BioNanoMed Catalunya Platform
The first platform that connects Catalan groups, university, hospitals and corporate research in nanotechnology applied to health and biotechnology.
European Perspectives in Personalised Medicine
The conference "European Perspectives in Personalised Medicine" took place on 12 -13 May 2011 in Brussels and gave substantial elements towards personalised medicine in Europe.
New wind on the ETPN Working Group dedicated to Regenerative Medicine
A new Chair as well as a new Vice-Chair has been elected to lead the RegMed WG
Info Consultation on future EU Research and Innovation Funding
Consultation: Green Paper on a Common Strategic Framework for future EU Research and Innovation Funding
Pfizer plans to close an R&D facility in the UK
Article from www.pharmalot.com (1st Februar 2011). As part of its ongoing effort to brace for the loss of the Lipitor patent, Pfizer now plans to close an R&D facility in Sandwick, Kent in the UK, which employs 2,400 jobs and was where Viagra was born.
MOLECULAR ENGINEERING SUMMER SCHOOL
Summerschool Biophysics of lipids and lipid-protein interactions: from biomembranes to molecular engineering, drug delivery and imaging, takes place in Utö Island, Finland, 4-11 June 2011.
Nanobiotix and the ETPN launch the first Nanomedicine TV
PARIS & BERLIN - Nanomed TV www.dailymotion.com/nanomedTV foresees to become the main hub for Nanomedicine thanks to its initiators, two major European players in nanomedicine: the European Technology Platform on Nanomedicine (ETPN) and Nanobiotix. Nanomed TV will make information accessible, aiming at answering what people need and wish to know about Nanomedicine.
Innovation Union: Commission launches consultation on active & healthy ageing
The European Commission is seeking the views of public and private organisations, companies and individual citizens on how Europe could scale up innovation to meet the challenges of the ageing population in Europe, and in particular on a pilot European Innovation Partnership (EIP) on active and healthy ageing, as set out in the Innovation Union Flagship Initiative, presented on 6 October by Maire Geoghegan Quinn, European Commissioner for Research, Innovation and Science and Antonio Tajani, Vice-President for Industry and Entrepreneurship.
Relevant Documents
 |
 |
|||
|
Expert Report 2009
|
White Paper to to the Horizon 2020 |
|||
 |
|
 |
|
 |
|
Strategic Research Agenda |
Vision Document |
ETP Nanomedicine Info Flyer |
|---|
